Robert L. Ferrara is Director at Phio Pharmaceuticals Corp. (PHIO). They have made 6 open-market trades across 1 company since 2021, most recently 2025-09-11.
CIK 0001792987
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $22K since 2021, never a sale. Across 6 scored buys the stock is up 1.2% at ninety days, and 3.9 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| PHIO | 38,766 | $34K |
Shares reported on the most recent Form 4, priced at the 2025-09-15 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 100% | 100% |
| Avg Move | -11.2% | +1.2% | +1.2% |
| Alpha | -74.9% | +0.3% | -3.9% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PHIO | BUY | 2025-06-10 | 2025-06-11 | $2.42 | $6K | -11.2% | +1.2% | +1.2% |
| PHIO | BUY | 2025-05-20 | 2025-05-21 | $1.82 | $5K | -11.2% | +1.2% | +1.2% |
| PHIO | BUY | 2023-06-14 | 2023-06-15 | $3.10 | $6K | -11.2% | +1.2% | +1.2% |
| PHIO | BUY | 2022-12-02 | 2022-12-05 | $0.41 | $2K | -11.2% | +1.2% | +1.2% |
| PHIO | BUY | 2022-11-23 | 2022-11-28 | $0.41 | $820 | -11.2% | +1.2% | +1.2% |
| PHIO | BUY | 2021-03-03 | 2021-03-03 | $3.15 | $2K | -11.2% | +1.2% | +1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.